Treatment of Recurrent or Metastatic Uterine Adenosarcoma

Table 4

Response rates with chemotherapy for recurrent or metastatic disease.

	1st line chemotherapy	All lines of chemotherapy (1, 2, 3)
Doxorubicin-based regimens
CR	2 (20%)	3 (18.7%) (AI (2), ADIC)
PR	2 (20%)	2 (12.5%) (AI, VAI)
(CR + PR)	4 (40%)	5 (31.2%)
SD	5 (50%)	9 (56.3%) (AI (4), ADIC, Dox (3), CyA)
(CR + PR + SD)	9 (90%)	14 (87.5%)
PD	1 (10%)	2 (12.5%) (AI, Dox)
Total patients	10	16
Gemcitabine/docetaxel
CR	1 (12.5%)	1 (7.1%)
PR	1 (12.5%)	1 (7.1%)
(CR + PR)	2 (25%)	2 (14.3%)
SD	3 (37.5%)	6 (42.9%)
(CR + PR + SD)	5 (62.5%)	8 (57.1%)
PD	3 (37.5%)	6 (42.9%)
Total patients	8	14
Platinum-based regimens
CR	0	0
PR	0	1 (20%) (Cis/Ifos)
(CR + PR)	0	1 (20%)
SD	3 (100%)	4 (80%) (Cis/Gem, Cis + XRT, carbo/taxol (2))
(CR + PR + SD)	3 (100%)	5 (100%)
PD	0	0
Total patients	3	5

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; AI, doxorubicin/ifosfamide; ADIC, doxorubicin/dacarbazine; VAI, vincristine/doxorubicin/ifosfamide; Dox, doxorubicin; CyA, doxorubicin/cyclophosphamide; Cis, cisplatin; Ifos, ifosfamide; Gem, gemcitabine; carbo, carboplatin; XRT, radiation; taxol, paclitaxel.